15
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2282 |
RPI-1
|
Others; Phospholipase; c-Met/HGFR; c-RET | Apoptosis; Metabolism; Others; Tyrosine Kinase/Adaptors |
RPI1 是特异性的、口服具有活力的 2-吲哚啉酮Ret 酪氨酸激酶抑制剂,具有抗肿瘤作用。它能够抑制人甲状腺髓样癌 TT 细胞增殖、Ret 酪氨酸磷酸化、Ret 蛋白表达及 PLCgamma、ERKs 和 AKT 的活化。 | |||
T8843 |
APS6-45
|
MAPK; Ras | GPCR/G Protein; MAPK |
APS6-45 是一种可口服的肿瘤校准抑制剂,可抑制 RAS/MAPK 信号传导并表现出抗肿瘤活性。 | |||
T21505 |
Suberoyl bis-hydroxamic acid
SBHA,软木肟酸,Suberohydroxamic acid |
Apoptosis; HDAC | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair |
Suberoyl bis-hydroxamic acid (SBHA) 是一种竞争性且可透过细胞的HDAC1和HDAC3抑制剂,ID50值分别为 0.25 μM 和 0.30 μM。它使肿瘤细胞易于凋亡并促进线粒体凋亡途径,可研究甲状腺髓样癌。 | |||
T13320 |
VU591 hydrochloride
|
Potassium Channel | Membrane transporter/Ion channel |
VU591 hydrochloride 是选择性的肾外髓钾通道抑制剂,IC50为 0.24 μM。 | |||
T23516 |
VU590
|
Potassium Channel | Membrane transporter/Ion channel |
VU590 是一种具有高效性和中等选择性的肾外髓质钾 ROMK (Kir1.1) 抑制剂。VU590 抑制 Kir7.1,可调节子宫肌层收缩力和黑皮质素信号传导。 | |||
TP1256 |
Adrenomedullin (AM) (22-52), human TFA
22-52-Adrenomedullin (human) (TFA) |
||
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFAis a kind of NH2 TFA truncated at the end of the quality of adrenal medullary analogue, is a kind of quality of adrenal medullary receptor antagonist. | |||
TP1824 |
Cerebellin
|
||
Cerebellin is a 16-amino acid peptide, originally isolated from rat cerebellum, whose presence has been recently demonstrated in the human adrenal glands and especially in medullary chromaffin cells. | |||
T79726 |
RET-IN-25
|
Others | Others |
RET-IN-25(化合物6b)是一种具有抗癌活性的RET激酶抑制剂。该化合物能够抑制甲状腺髓样癌(MTC),在TT(C634R) MTC细胞系中的IC50值分别为3.6 μM(3天)和3.0 μM(6天)。 | |||
T13370 |
YM-46303
|
AChR | Neuroscience |
YM-46303 是一种具有选择性和有效性的毒蕈碱受体拮抗剂,对 M3 受体表现出较高的亲和力。YM-46303 可用于研究髓状大鼠心动过缓。 | |||
T62760 |
ROMK-IN-32
|
Others | Others |
ROMK-IN-32 是一种肾外髓质钾通道 (ROMK) 抑制剂 (IC50: 35 nM),也能够抑制 hERG (IC50: 22 μM)。 | |||
T60493 |
Guaiacol Carbonate
|
Others | Others |
Guaiacol Carbonate 是一种祛痰剂,其作用是通过胃的反射作用,通过胃神经到达延髓中枢,然后再通过外周进入呼吸道,从而起到祛痰作用。 | |||
T62544 |
MK-8153
|
Others | Others |
MK-8153 是一种选择性的、有效的、口服具有活力的肾外髓质钾通道 (ROMK) 抑制剂,作用于 ROMK EP (IC50: 5 μM) 和 hERG EP (IC50: 34 μM)。MK-8153 能够用作利尿剂。 | |||
T78203 |
NSC194598
|
Others | Others |
NSC194598是一种p53 DNA结合抑制剂,其体外和体内抑制p53序列特异性DNA结合的IC50值分别约为180 nM和2-40 μM。在人甲状腺髓样癌TT细胞中,NSC194598能够干扰突变RET基因的转录激活。该化合物可应用于研究放射及化学疗法对正常组织造成的急性毒性。 | |||
T22552 |
AD57 (hydrochloride)
|
Others | Others |
AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase RET, weakens the activity of numero | |||
T63183 |
RET-IN-9
|
Others | Others |
RET-IN-9 是一种 RET 的有效抑制剂。其中 RET 激酶是一种单通道跨膜受体酪氨酸激酶,在肾脏和肠神经系统的发育以及维持神经、内分泌、造血和男性生殖系统的体内平衡中发挥着重要作用。RET-IN-9 具有潜力进行 RET 相关疾病的研究(包括非小细胞肺癌和甲状腺髓样癌)。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00122 |
CD30 Ligand/TNFSF8 Protein, Human, Recombinant (His)
CD153,CD30LGMGC138144,CD30LG,CD30-L,CD30 Ligand,CD30L,TNFSF8 |
Human | HEK293 Cells |
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells.CD30L is a cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells. | |||
TMPY-01246 |
MARCO Protein, Mouse, Recombinant (His)
AI323439,Ly112,macrophage receptor with collagenous structur... |
Mouse | HEK293 Cells |
Macrophage receptor MARCO, also known as Macrophage receptor with collagenous structure and Marco, is a single-pass type II membrane protein. MARCO is a member of the class A scavenger receptor family and is part of the innate antimicrobial immune system. It is expressed in subpopulations of macrophages in the spleen and the medullary cord of lymph nodes. Although it is expressed on subsets of macrophages, it can be upregulated on other macrophages after bacterial infection. The strategic positi... |